Howlett M R, Skellern G G, Auld W H, Murdoch W R
Department of Clinical Biochemistry, Crosshouse Hospital, Kilmarnock, UK.
Eur J Clin Pharmacol. 1990;38(6):583-6. doi: 10.1007/BF00278586.
The pharmacokinetics and metabolism of orally administered bumetanide were studied in five healthy subjects and in five patients with renal insufficiency. Healthy subjects excreted 51% of the dose as unchanged drug in the urine, whilst the patients with renal insufficiency excreted only 11% of the dose as bumetanide. Similarly the urinary excretion of the gamma-hydroxybutyl metabolite was reduced from 6% in healthy subjects to 2.3% in patients with renal impairment. In both groups of subjects the mean elimination half-life of the metabolite was greater than for bumetanide. The results indicate a possible accumulation of bumetanide and metabolite in patient with renal failure.
